These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27297910)

  • 61. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
    Seow CH; Newman A; Irwin SP; Steinhart AH; Silverberg MS; Greenberg GR
    Gut; 2010 Jan; 59(1):49-54. PubMed ID: 19651627
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis.
    Hindson J
    Nat Rev Gastroenterol Hepatol; 2023 Sep; 20(9):559. PubMed ID: 37553497
    [No Abstract]   [Full Text] [Related]  

  • 63. Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.
    Hanzel J; Drobne D
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1469-1470. PubMed ID: 37243472
    [No Abstract]   [Full Text] [Related]  

  • 64. Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's reply.
    Fumery M; Roblin X
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1471-1472. PubMed ID: 37243470
    [No Abstract]   [Full Text] [Related]  

  • 65. Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis.
    Mantzaris GJ; Papamichael K
    Aliment Pharmacol Ther; 2022 Aug; 56(4):735-736. PubMed ID: 35879902
    [No Abstract]   [Full Text] [Related]  

  • 66. Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis-Author's reply.
    Taxonera C
    Aliment Pharmacol Ther; 2022 Aug; 56(4):737-738. PubMed ID: 35879906
    [No Abstract]   [Full Text] [Related]  

  • 67. Monoclonal Antibody Risankizumab for Ulcerative Colitis.
    Kaplan GG
    JAMA; 2024 Sep; 332(11):877-878. PubMed ID: 39037779
    [No Abstract]   [Full Text] [Related]  

  • 68. Editorial: LAG-3-depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?
    Lobatón T; Truyens M
    Aliment Pharmacol Ther; 2023 Aug; 58(3):359-360. PubMed ID: 37452596
    [No Abstract]   [Full Text] [Related]  

  • 69. Reply: To PMID 25917786.
    Brandse JF; D'Haens GR
    Gastroenterology; 2015 Dec; 149(7):1989-90. PubMed ID: 26515491
    [No Abstract]   [Full Text] [Related]  

  • 70. Editorial: therapeutic drug monitoring for golimumab - ready for prime time?
    Roblin X; Le Roy B; Paul S
    Aliment Pharmacol Ther; 2020 Sep; 52(6):1078-1079. PubMed ID: 33119158
    [No Abstract]   [Full Text] [Related]  

  • 71. Expert Commentary on the Management of Ulcerative Colitis.
    Lightner AL
    Dis Colon Rectum; 2018 Sep; 61(9):1013-1015. PubMed ID: 30086049
    [No Abstract]   [Full Text] [Related]  

  • 72. Comparative Effectiveness Research to Position Therapies in Ulcerative Colitis: How Fair Are the Comparisons?
    Alsoud D; Verstockt B; Vermeire S
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1372-1373. PubMed ID: 35850410
    [No Abstract]   [Full Text] [Related]  

  • 73. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
    Ungar B; Kopylov U; Engel T; Yavzori M; Fudim E; Picard O; Lang A; Williet N; Paul S; Chowers Y; Bar-Gil Shitrit A; Eliakim R; Ben-Horin S; Roblin X
    Aliment Pharmacol Ther; 2017 Jan; 45(2):276-282. PubMed ID: 27862102
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Moćko P; Kawalec P; Pilc A
    Pharmacotherapy; 2016 Aug; 36(8):870-9. PubMed ID: 27312826
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.
    Verstockt B; Van Assche G; Vermeire S; Ferrante M
    Expert Opin Biol Ther; 2017 Jan; 17(1):31-47. PubMed ID: 27817215
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Emerging biologics in inflammatory bowel disease.
    Chan HC; Ng SC
    J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
    Mitrev N; Leong RW
    Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
    Khorrami S; Ginard D; Marín-Jiménez I; Chaparro M; Sierra M; Aguas M; Sicilia B; García-Sánchez V; Suarez C; Villoria A; Taxonera C; Velasco-Guardado A; Martínez-González J; Gisbert JP
    Inflamm Bowel Dis; 2016 Jul; 22(7):1662-9. PubMed ID: 27306072
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by TNF targeting molecules: Therapeutic implications.
    Szondy Z; Pallai A
    Pharmacol Res; 2017 Jan; 115():124-132. PubMed ID: 27888159
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index.
    Bodini G; Giannini EG; De Maria C; Dulbecco P; Furnari M; Marabotto E; Savarino V; Savarino E
    Dig Liver Dis; 2017 Feb; 49(2):175-180. PubMed ID: 27864028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.